This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

IPO Watch: 2011

AcelRx Pharmaceuticals

IPO Filing Date: Nov. 12, 2010

Expected IPO Date: Feb. 7, 2011



Amount of Proceeds Sought: ~$75 million

Expected Offering Price: $12 to $14

Expected Number of Shares to Be Sold: ~ 5.8 million

Use of Proceeds: To fund phase 3 development of lead, post-surgery pain treatment product ARX-01; working capital; and other general corporate purposes.



Expected Ticker Symbol: ACRX (ACRX) (NASDAQ)



Lead Underwriters: Piper Jaffray (PJC)

Co-Managers: Canaccord Genuity, Cowen and Company (COWN), JMP Securities (JMP)



About the Company: AcelRx is a drug company that focuses on developing and commercializing pain treatment therapies.

Currently it has three products in the pipeline, but not yet on the market. The lead product is post-surgery pain treatment product ARX-01. Its ARX-02 product treats pain in cancer patients and its ARX-03 product treats pain and anxiety caused by painful physician procedures.

The company aims to bring its products to market amid a burgeoning, global post-surgical pain market. According to AcelRx, the post-operative pain market in the U.S., Europe and Japan is expected to reach $6.5 billion by 2018.

Given that the company isn't selling any products yet, it hasn't generated any revenue since it was founded in Jul. 2005. AcelRx has experienced significant net losses every year since its inception. It could fail as a business if the company doesn't successfully commercialize its products.

Competitors: The main competitor against the company's ARX-01 product is the widely-used IV PCA pump. Leading manufacturers of IV PCA pumps include Hospira (HSP), CareFusion (CFN), Baxter International (BAX) and Smiths Medical (SMGZY).

Potential competitors for ARX-01 that are currently also being developed include Ionsys, which was originally developed by Johnson & Johnson (JNJ) subsidiaries.

Potential competitors for the company's ARX-02 product include Actiq and Fentora, made by Cephalon (CEPH); Onsolis, made by BioDelivery Sciences International (BDSI), and Abstral, made by ProStrakan Group (PKNGF).

IPO Scorecard:



Actual IPO Date: Feb. 11

Actual Proceeds Raised: $40 million

Actual Offering price: $5

Actual Number of Shares Sold: 8 million



First Day Closing Price: $4.55

IPO First Day Return: -9

6 of 9

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,079.57 -42.44 -0.25%
S&P 500 1,996.74 -3.38 -0.17%
NASDAQ 4,557.6950 -11.9260 -0.26%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs